American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility

Journal of Clinical Oncology

Volumn 33, Issue 31, 2015, Pages 3660-3667

  Robson, Mark E ^a,b   Bradbury, Angela R ^c   Arun, Banu ^d   Domchek, Susan M ^c   Ford, James M ^e   Hampel, Heather L ^f   Lipkin, Stephen M ^b   Syngal, Sapna ^g   Wollins, Dana S ^h   Lindor, Noralane M ⁱ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; GENE TECHNOLOGY; GENETIC SCREENING; GENOMICS; GERMLINE MUTATION; HUMAN; MEDICAL EDUCATION; MEDICAL SOCIETY; ONCOLOGIST; ONCOLOGY; PRIORITY JOURNAL; QUALITY CONTROL; SOMATIC MUTATION; EDUCATION; GENETIC PREDISPOSITION; GENETICS; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HUMAN GENOME; LEGISLATION AND JURISPRUDENCE; NEOPLASM; ORGANIZATION AND MANAGEMENT; RISK ASSESSMENT; UNITED STATES;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOME, HUMAN; GENOMICS; GERM-LINE MUTATION; HEALTH SERVICES ACCESSIBILITY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PATIENT PROTECTION AND AFFORDABLE CARE ACT; QUALITY ASSURANCE, HEALTH CARE; RISK ASSESSMENT; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84947279527     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.0996     Document Type: Article

References (29)

1. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. J Clin Oncol 14:1730-1736, 1996
2. American Society of Clinical Oncology: American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility. J Clin Oncol 21:2397-2406, 2003
3. Robson ME, Storm CD, Weitzel J, et al: American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. J Clin Oncol 28:893-901, 2010
4. Garraway LA, Verweij J, Ballman KV: Precision oncology: An overview. J Clin Oncol 31:1803-1805, 2013
5. Bombard Y, Robson M, Offit K: Revealing the incidentalome when targeting the tumor genome. JAMA 310:795-796, 2013
6. Stadler ZK, Schrader KA, Vijai J, et al: Cancer genomics and inherited risk. J Clin Oncol 32:687-698, 2014
7. Garraway LA: Genomics-driven oncology: Framework for an emerging paradigm. J Clin Oncol 31:1806-1814, 2013
8. Parsons DW, Roy A, Plon SE, et al: Clinical tumor sequencing: An incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. J Clin Oncol 32:2203-2205, 2014
9. Domchek SM, Bradbury A, Garber JE, et al: Multiplex genetic testing for cancer susceptibility: Out on the high wire without a net? J Clin Oncol 31:1267-1270, 2013
10. Green RC, Berg JS, Grody WW, et al: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15:565-574, 2013
11. Wolf SM, Annas GJ, Elias S: Point-counterpoint: Patient autonomy and incidental findings in clinical genomics. Science 340:1049-1050, 2013
12. Weiner C: Anticipate and communicate: Ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). Am J Epidemiol 180:562-564, 2014
13. Lu KH, Wood ME, Daniels M, et al: American Society of Clinical Oncology expert statement: Collection and use of a cancer family history for oncology providers. J Clin Oncol 32:833-840, 2014
14. Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975, 2010
15. de Jong AE, Hendricks YM, Kleibeuker JH, et al: Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130:665-671, 2006
16. Kurian AW, Hare EE, Mills MA, et al: Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32:2001-2009, 2014
17. Tung N, Battelli C, Allen B, et al: Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121:25-33, 2015
18. Plon SE, Cooper HP, Parks B, et al: Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med 13:148-154, 2011
19. Cragun D, Radford C, Dolinsky JS, et al: Panel-based testing for inherited colorectal cancer: A descriptive study of clinical testing performed by a US laboratory. Clin Genet 86:510-520, 2014
20. Robson M: Multigene panel testing: Planning the next generation of research studies in clinical cancer genetics. J Clin Oncol 32:1987-1989, 2014
21. Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP working group. Genet Med 11:3-14, 2009
22. National Institutes of Health, Secretary's Advisory Committee on Genetic Testing: Enhancing the oversight of genetic tests: Recommendations of the SACGT. http://osp.od.nih.gov/sites/default/files/oversight-report.pdf
23. Federal Trade Commission: FTC facts for consumers: At-home genetic tests - A healthy dose of skepticism may be the best prescription. http://osp.od.nih.gov/sites/default/files/DTC-Consumer-Alert-Jul06.pdf
24. US Food and Drug Administration: Inspections, compliance, enforcement, and criminal investigations: Warning letter. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm376296.htm
25. US Food and Drug Administration: Draft guidance for industry, Food and Drug Administration staff, and clinical laboratories: Framework for regulatory oversight of laboratory developed tests (LDTs). http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416685.pdf
26. Accreditation Council of Graduate Medical Education: ACGME program requirements for graduate medical education in hematology and medical oncology (internal medicine). https://www.acgme.org/acgmeweb/portals/0/pfassets/programrequirements/155-hematology-oncology-int-med-2016.pdf
27. Green BB, Coronado GD, Devoe JE, et al: Navigating the murky waters of colorectal cancer screening and health reform. Am J Public Health 104:982-986, 2014
28. Zhang SQ, Polite BN: Achieving a deeper understanding of the implemented provisions of the Affordable Care Act. Am Soc Clin Oncol Ed Book e472-e477, 2014
29. Cigna: Genetic testing and counseling program. http://www.cigna.com/healthcare-professionals/resources-for-health-care-professionals/genetic-testing-and-counseling-program